Peroxisome proliferator-activated receptor-α (PPARα), PPARδ and PPARγ are transcription
factors that regulate gene expression following ligand activation. PPARα increases cellular …

Abstract Sodium–glucose cotransporter 2 (SGLT2) inhibitors are effective antidiabetic
therapies in patients with type 2 diabetes mellitus and are associated with improved …

Obesity and heart failure with preserved ejection fraction (HFpEF) represent two
intermingling epidemics driving perhaps the greatest unmet health problem in …

Type 2 diabetes mellitus is a risk factor for incident heart failure and increases the risk of
morbidity and mortality in patients with established disease. Secular trends in the …

The kidney has a pivotal role in maintaining glucose homeostasis by using glucose as a
metabolic fuel, by producing glucose through gluconeogenesis, and by reabsorbing all …

Epidemiologic and clinical data from the last 2 decades have shown that the prevalence of
heart failure in diabetes is very high, and the prognosis for patients with heart failure is …

Even in the absence of coronary artery disease and hypertension, diabetes mellitus (DM)
may increase the risk for heart failure development. This risk evolves from functional and …

Heart failure is a complex clinical syndrome, the incidence and prevalence of which is
increased in diabetes mellitus, pre-diabetes, and obesity. Although this may arise from …

Aims To examine the manifestation of cardiovascular or renal disease (CVRD) in patients
with type 2 diabetes (T2D) initially free from CVRD as well as the mortality risks associated …

Although cardiovascular (CV) mortality is the principal cause of death in individuals with type
2 diabetes (T2DM), reduction of plasma glucose concentration has little effect on CV disease …